Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
PHASE3RecruitingINTERVENTIONAL
Enrollment
25
Participants
Timeline
Start Date
January 6, 2025
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2026
Conditions
Breast Cancer Metastatic
Interventions
DRUG
68Ga-DOTATOC
Slow direct intravenous injection
Trial Locations (1)
38043
RECRUITING
CHU Grenoble Alpes, Grenoble
All Listed Sponsors
lead
University Hospital, Grenoble
OTHER
NCT06611891 - Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter